Viridian Therapeutics Inc. reported its third quarter 2025 financial results and recent business progress. The company completed a set of financing transactions in October 2025, securing access to up to $889 million in potential capital through equity, royalty, and credit arrangements. Viridian also amended its credit facility with Hercules Capital, providing up to $300 million in available capital and extending the interest-only payment period. The company announced the successful submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration for veligrotug in thyroid eye disease (TED), with preparations underway for a potential U.S. commercial launch in mid-2026, pending approval under a Priority Review timeline. Topline data readouts for subcutaneous VRDN-003 were accelerated, with REVEAL-1 data expected in Q1 2026 and REVEAL-2 in Q2 2026, after both studies exceeded enrollment targets. Viridian stated that its current cash, anticipated near-term royalty milestones, and expected commercial revenues from veligrotug and VRDN-003, if approved, are projected to fund its business plans through profitability.